Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives.
Price History & Performance
|Historical stock prices|
|Current Share Price||€20.50|
|52 Week High||€19.18|
|52 Week Low||€26.94|
|1 Month Change||-0.63%|
|3 Month Change||-0.97%|
|1 Year Change||-23.36%|
|3 Year Change||-11.52%|
|5 Year Change||9.01%|
|Change since IPO||680.95%|
Recent News & Updates
Calculating The Intrinsic Value Of Grifols, S.A. (BME:GRF)
Does the October share price for Grifols, S.A. ( BME:GRF ) reflect what it's really worth? Today, we will estimate the...
Is Grifols (BME:GRF) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Calculating The Intrinsic Value Of Grifols, S.A. (BME:GRF)
How far off is Grifols, S.A. ( BME:GRF ) from its intrinsic value? Using the most recent financial data, we'll take a...
|GRF||ES Biotechs||ES Market|
Return vs Industry: GRF underperformed the Spanish Biotechs industry which returned 0.3% over the past year.
Return vs Market: GRF underperformed the Spanish Market which returned 25% over the past year.
Stable Share Price: GRF is not significantly more volatile than the rest of Spanish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: GRF's weekly volatility (4%) has been stable over the past year.
About the Company
|1940||23,431||Raimon Grifols Roura||https://www.grifols.com|
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions.
Grifols Fundamentals Summary
|GRF fundamental statistics|
Is GRF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GRF income statement (TTM)|
|Cost of Revenue||€2.87b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.98|
|Net Profit Margin||12.83%|
How did GRF perform over the long term?See historical performance and comparison
1.8%Current Dividend Yield
Is Grifols undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GRF (€20.5) is trading above our estimate of fair value (€17.27)
Significantly Below Fair Value: GRF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GRF is good value based on its PE Ratio (21x) compared to the European Biotechs industry average (30.6x).
PE vs Market: GRF is good value based on its PE Ratio (21x) compared to the Spanish market (23.3x).
Price to Earnings Growth Ratio
PEG Ratio: GRF is poor value based on its PEG Ratio (1.2x)
Price to Book Ratio
PB vs Industry: GRF is good value based on its PB Ratio (2.7x) compared to the XE Biotechs industry average (4.7x).
How is Grifols forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRF's forecast earnings growth (16.9% per year) is above the savings rate (0.9%).
Earnings vs Market: GRF's earnings (16.9% per year) are forecast to grow faster than the Spanish market (16.5% per year).
High Growth Earnings: GRF's earnings are forecast to grow, but not significantly.
Revenue vs Market: GRF's revenue (7.7% per year) is forecast to grow faster than the Spanish market (6.4% per year).
High Growth Revenue: GRF's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GRF's Return on Equity is forecast to be low in 3 years time (15.2%).
How has Grifols performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRF has high quality earnings.
Growing Profit Margin: GRF's current net profit margins (12.8%) are higher than last year (10.4%).
Past Earnings Growth Analysis
Earnings Trend: GRF's earnings have grown by 2.4% per year over the past 5 years.
Accelerating Growth: GRF's earnings growth over the past year (19.9%) exceeds its 5-year average (2.4% per year).
Earnings vs Industry: GRF earnings growth over the past year (19.9%) underperformed the Biotechs industry 29.6%.
Return on Equity
High ROE: GRF's Return on Equity (10.8%) is considered low.
How is Grifols's financial position?
Financial Position Analysis
Short Term Liabilities: GRF's short term assets (€3.2B) exceed its short term liabilities (€1.9B).
Long Term Liabilities: GRF's short term assets (€3.2B) do not cover its long term liabilities (€7.4B).
Debt to Equity History and Analysis
Debt Level: GRF's debt to equity ratio (98.3%) is considered high.
Reducing Debt: GRF's debt to equity ratio has reduced from 136.6% to 98.3% over the past 5 years.
Debt Coverage: GRF's debt is not well covered by operating cash flow (13.3%).
Interest Coverage: GRF's interest payments on its debt are well covered by EBIT (5x coverage).
What is Grifols's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GRF's dividend (1.76%) is higher than the bottom 25% of dividend payers in the Spanish market (1.47%).
High Dividend: GRF's dividend (1.76%) is low compared to the top 25% of dividend payers in the Spanish market (5.42%).
Stability and Growth of Payments
Stable Dividend: GRF has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: GRF's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (37.1%), GRF's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GRF's dividends in 3 years are forecast to be well covered by earnings (35% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raimon Grifols Roura (57 yo)
Mr. Raimon Grifols Roura has been the Co-Chief Executive Officer of Grifols, S.A. since January 1, 2017 and served as its Co-Chairman. Mr. Roura was a Patner at Osborne Clarke Spain. Mr. Roura serves as th...
CEO Compensation Analysis
Compensation vs Market: Raimon's total compensation ($USD1.36M) is below average for companies of similar size in the Spanish market ($USD3.21M).
Compensation vs Earnings: Raimon's compensation has been consistent with company performance over the past year.
Experienced Management: GRF's management team is seasoned and experienced (13.8 years average tenure).
Experienced Board: GRF's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Grifols, S.A.'s employee growth, exchange listings and data sources
- Name: Grifols, S.A.
- Ticker: GRF
- Exchange: BME
- Founded: 1940
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €11.886b
- Shares outstanding: 682.48m
- Website: https://www.grifols.com
Number of Employees
- Grifols, S.A.
- Avinguda de la Generalitat, 152
- Parc empresarial Can Sant Joan
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 17:51|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.